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Abstract Earlier studies showed that treatment of LA-N-1
cells with TPA, a tumoral promoter, leads to the stimulation
of a G protein-regulated phospholipase D (PLD) in the nuclei.
Now we demonstrate that retinoic acid, a cellular di¡erentiation
inducing agent, activates a nuclear oleate-dependent PLD in
LA-N-1 cells. Treatment of the nuclei with retinoic acid induces
the breakdown of phosphatidylcholine (PtdCho). Our results
indicate that PLD is regulated di¡erentially depending on the
nature of the stimulatory agent. These results strongly suggest
the existence of two nuclear PLD isoforms in LA-N-1 nuclei
that hydrolyze PtdCho.
* 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
All-trans-retinoic acid (atRA), the active metabolite from
vitamin A, plays a key role in development and induces
long-term cellular responses such as di¡erentiation or apopto-
sis [1]. In the human LA-N-1 neuroblastoma cell line, atRA
induces concentration- and time-dependent di¡erentiation re-
sulting in complete growth arrest and neuritic phenotype-like
extensions [2]. These e¡ects of RA are mediated through the
activation of two types of nuclear receptors, retinoic acid re-
ceptors (RARs) and retinoic X receptors (RXRK, L and Q) [3].
Both types of receptors belong to the steroid/thyroid receptor
superfamily [4,5]. RAR binds either atRA or cis-RA with high
a⁄nity, heterodimerizes with RXR and acts as ligand-depen-
dent transcription factor [6].
Phospholipases C and D (PLC, PLD) hydrolyze phospho-
lipids to produce diacylglycerol (DAG) and phosphatidic acid
(PtdOH), respectively [7]. Prior studies have reported that
PLC or PLD activation is dependent on the physiological
state of LA-N-1 cells [8]. Furthermore, our recent data indi-
cate that TPA, a tumoral promoter, stimulates a G protein-
dependent PLD in nuclei of LA-N-1 proliferative cells [9]. In
order to gain insights into the regulation of phospholipases in
the nuclei of di¡erentiating cells, we investigated the e¡ect of
atRA on LA-N-1 nuclear PLD activity using a transphospha-
tidylation assay [10]. In this, a primary alcohol, like ethanol or
butanol-1, acts as a preferential nucleophilic acceptor for the
phosphatidyl moiety resulting from mediating PLD break-
down, to produce essentially the non-metabolizable product
phosphatidylalcohol, instead of PtdOH. Our results reveal
that the treatment of whole cells or intact nuclei with atRA
in the presence of ethanol leads to the production of nuclear
DAG and phosphatidylethanol (PtdEtOH) suggesting the ac-
tivation of PLC and demonstrating that of PLD. In nuclei of
atRA-di¡erentiated LA-N-1 cells, the production of PtdEtOH
is not a¡ected by the addition of the non-hydrolyzable nucle-
otide guanosine triphosphate (GTP)QS. However, that of ole-
ate induces a strong enhancement of PtdEtOH, demonstrating
that a nuclear oleate-regulated PLD is speci¢cally stimulated.
Moreover, in atRA-treated nuclei, an increase in the produc-
tion of free choline is observed indicating that phosphatidyl-
choline (PtdCho) was the main substrate for the LA-N-1 ole-
ate-dependent PLD.
2. Materials and methods
2.1. Cells and reagents
Human neuroblastoma LA-N-1 cells were obtained from Dr.
Seeger, University of California at Los Angeles. Leibovitz’s L-15 me-
dium and fetal calf serum were supplied by Life Technologies
(Eragny, France). Streptomycin, penicillin, trypsin inhibitor, phenyl-
methylsulfonyl£uoride, atRA, adenosine triphosphate (ATP), GTPQS,
PtdOH, dipalmitin and Dowex 50U8 WHþ were purchased from
Sigma Chemical (St. Louis, MO, USA); PtdEtOH from Tebu S.A.
(Le Parray en Yvelines, France); silica gel plates G 60 (Kieselgel 60,
20U20 cm; 250 WM) from Merck (Darmstadt, Germany);
[3H]choline, [3H]palmitic acid from NEN Life Sciences Products
(Paris, France) and 1-2-di-[1-14C]oleyl PtdCho from Amersham Life
Sciences (Oakville, Canada).
2.2. LA-N-1 cell cultures and preparation of nuclei
LA-N-1 cells were maintained in culture with Leibovitz’s L-15 me-
dium containing 15% fetal calf serum. The medium was renewed at
days 2 and 5. At day 5, the cells were prelabeled with [3H]palmitic
acid or with [3H]choline (speci¢c activity 60 Ci/mmol each) for 48 h.
At day 7, the medium was removed and [3H]palmitic acid labeled cells
were either untreated or incubated with dimethyl sulfoxide (DMSO
0.01%) or 10 WM RA in DMSO (0.01%) respectively for 30 min in the
presence of 1% ethanol. Di¡erentiation of LA-N-1 cells was per-
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formed by adding to the culture medium 10 WM RA in DMSO
(0.01%) at day 2 for 5 days. LA-N-1 nuclei were isolated according
to the method of Antony et al. [9]. Isolated nuclei were suspended in
50 mM Tris^HCl, 4.0 mM MgCl2, 2.0 mM CaCl2, 0.25 M saccharose,
pH 7.5. Whole cells or intact nuclei were incubated with atRA ac-
cording to experimental requirements. Cell culture and incubations
were conducted at 37‡C.
2.3. Separation of nuclear PtdOH, PtdEtOH and DAG
Nuclear lipids were extracted by the method of Kiss and Crilly [11]
and lipid carrier standards were added. PtdOH, PtdEtOH and DAG
were separated by thin layer chromatography on silica gel G plates
using a double development system and the radioactivity of products
quanti¢ed as reported [9].
2.4. Determination of nuclear PLD activities
The determination of the activation of nuclear PLD was performed
as previously described [9]. In vitro determination of either GTPQS/
phosphatidylinositol 4,5-diphosphate (PIP2) or oleate-dependent PLD
speci¢c activities was achieved on nuclei of control or of 5 days atRA-
treated LA-N-1 cells. The incubations for the PLD activity measure-
ments contained 50 mM dimethylglutarate pH 6.5, a substrate co-
sonicate of 0.75 mM 1-2-di-[1-14C]oleyl PtdCho (speci¢c activity 114
mCi/mmol), 10 mM ethylenediamine tetraacetic acid (EDTA), 25 mM
NaF and 20 Wg of nuclear protein either with 100 WM of GTPQS/PIP2
or 1.2 mM oleate in the presence of 1% ethanol for 30 min [12].
PtdOH and PtdEtOH were separated from other lipids and their
radioactivity quanti¢ed as reported above.
2.5. Quanti¢cation of PtdCho hydrolysis in atRA-treated nuclei
Nuclei of [3H]choline prelabeled cells were directly incubated with
DMSO or atRA in DMSO for 1 h. Water-soluble choline-containing
compounds were separated by ion exchange chromatography on
Dowex-50-WHþ [13] and the radioactivity on aliquots of each frac-
tion measured by scintillation counting.
2.6. Protein determination
The protein content was determined by the method of Lowry et al.
[14] using bovine serum albumin as the standard.
2.7. Statistics
The data represent the mean of at least three experiments per-
formed in triplicate and analyzed utilizing Student’s test.
3. Results
3.1. Production of DAG, PtdOH and PtdEtOH in
LA-N-1 nuclei
The treatment of the [3H]palmitic acid labeled cells with
atRA in the presence of ethanol leads to an increase in the
production of DAG and PtdEtOH in the nuclei, but not
PtdOH (Fig. 1A). A similar enhancement of both compounds
is observed when isolated nuclei are incubated with atRA
(Fig. 1B). However, the level of PtdEtOH produced in
atRA-treated nuclei is much lower than in stimulated cells
suggesting that an essential cofactor may be lost during the
preparation of nuclei. These results indicate that the binding
of atRA with nuclear RARs activates a nuclear PLD. DAG
production may be the consequence of stimulation of a PLC
and/or the sequential activation of a PLD and a phosphati-
date phosphohydrolase.
3.2. PtdCho hydrolysis in atRA-treated nuclei
Prior studies have shown that PLD acts preferentially on
PtdCho [15]. We therefore investigated whether this phospho-
lipid is a substrate for the nuclear PLD. The stimulation with
atRA of [3H]choline prelabeled nuclei induces a 30% increase
in the production of water-soluble choline compounds, phos-
phocholine and free choline (Fig. 2), suggesting that PtdCho
is a target for the nuclear PLC and PLD.
3.3. Regulation of the nuclear PLD
Two essential modes of regulation of PLD (protein G- and
oleate-dependent enzymes) have been observed in nuclei [15].
We searched for the in vitro e¡ect of GTPQS/PIP2 and oleate
on the PLD activity in the nuclei of control and atRA-treated
cells in the presence of ethanol and inhibitor of PtdOH phos-
phatase activity to carry out the experiment at optimal con-
ditions. We monitored the production of the sum of PtdOH
and PtdEtOH as index of PLD activity. Results show that the
speci¢c activity of the oleate-dependent PLD in nuclei of con-
trol cells is about 20-fold higher than that of GTPQS/PIP2.
The treatment of the cells with atRA for 5 days provokes a
two-fold increase in the speci¢c activity of the nuclear oleate-
dependent PLD whereas no e¡ect is observed on that of the
GTPQS/PIP2-dependent one (Fig. 3). In the present cellular
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Fig. 1. E¡ect of atRA on the production of DAG, PtdOH and
PtdEtOH in LA-N-1 nuclei. A represents the formation of nuclear
lipid compounds resulting from the incubations of whole cells
whereas B depicts that of isolated nuclei. The experimental details
are described in Section 2. Results are the meansRS.E.M. of three
experiments and represent the percentage increase of radioactivity of
each lipid relative to total nuclear lipids. The amount of the total
radioactivity in the nuclear fraction is 140 000 cpm (A) and 100 000
cpm (B). The open bars represent the control incubations and the
¢lled ones that of the atRA-treated cells or nuclei. ***P6 0.001;
**P6 0.01.
FEBS 27157 11-4-03
P. Antony et al./FEBS Letters 541 (2003) 93^9694
model, the oleate-dependent PLD preferentially catalyzes the
formation of PtdEtOH as compared to PtdOH in nuclei (ratio
3/1, data not shown). Thus LA-N-1 cellular di¡erentiation
with atRA induces speci¢cally the activation of an oleate-de-
pendent PLD in the nuclei.
4. Discussion
The regulation of the PLD isoform activities is controlled
by multiple compounds such as protein kinases C, G proteins
and various lipids [15,16]. The signaling pathway involved in
the activation of G protein-dependent PLDs, particularly the
PLD1 isoform, has been extensively studied. However, little is
known about the molecular mechanisms that control the ole-
ate-dependent PLD [17]. Since neuroblastoma cell lines repre-
sent a well-established model for deciphering the molecular
mechanisms implicated in neural cell di¡erentiation [18], we
investigated the regulation of PLD activity in the nuclei of
LA-N-1 cells induced to di¡erentiate with atRA.
Our results of transphosphatidylation assays indicate the
presence of a PLD activated by atRA in nuclei (Fig. 1), be-
cause PtdEtOH is not dephosphorylated into DAG by a phos-
phatidate phosphohydrolase, and remains a stable molecule.
The molecular mechanisms leading to DAG formation may
result in the stimulation of a PLC and/or a dephosphorylation
of PtdOH by a PtdOH phosphohydrolase activity. This latter
may explain the absence of PtdOH formation. The activity of
PLD may be regulated by either small G proteins like RhoA
[19^21] or by oleate as reported in rat brain neuronal nuclei
[22]. We provided compelling evidence that the di¡erentiation
of LA-N-1 cells induced by atRA speci¢cally stimulates a
nuclear oleate-dependent PLD (Fig. 3). Incubations of intact
nuclei with atRA, ATP and GTPQS in the presence of ethanol
do not provoke an increase of PtdEtOH as compared to atRA
alone (data not shown) [9]. Therefore we believe that this
PLD isoform is di¡erent from the one stimulated by phorbol
esters [9] and the one present in HL60 cells because it is in-
sensitive to GTPQS/PIP2 [23]. Furthermore, two forms of PLD
have been described in rat hepatocyte nuclei [24]. One is acti-
vated by the nuclear adenosine diphosphate (ADP) ribosyla-
tion (ARF), GTP and PIP2, and is associated with cell pro-
liferation, whereas the activity of the oleate-dependent PLD
remained constant during the cell cycle progression in liver
regeneration. Together these observations suggest the presence
in LA-N-1 nuclei of two PLD isoforms, a G protein-depen-
dent one that is activated by TPA during cellular proliferation
and an oleate-dependent PLD stimulated by atRA during
cellular di¡erentiation. It should be emphasized that no in-
crease of PtdOH is detected when [14C]PtdCho labeled LA-
N-1 cells are incubated in the presence of oleate, but without
ethanol [25]. Therefore, this experimental procedure employed
by Singh et al. does not permit any conclusion about an in
vitro oleate-dependent PLD activity involvement in whole
cell, because the level of PtdEtOH is not measured. Whether
our ¢nding is a speci¢c phenomenon to the LA-N-1 nucleus,
remains to be clari¢ed.
We showed that the treatment of LA-N-1 nuclei with atRA
leads to an enhancement of choline and phosphocholine pro-
duction (Fig. 2). Similar results are obtained with TPA as
agonist [26] indicating that PtdCho is a substrate for both
oleate- and G protein-dependent PLDs. However, the speci¢c
activity of the nuclear oleate-regulated PLD increases during
atRA cellular treatment but not that of the GTPQS/PIP2-de-
pendent one (Fig. 3). We showed that the oleate-dependent
PLD catalyzes preferentially the formation of PtdEtOH as
compared to PtdOH in nuclei of atRA-di¡erentiated LA-
N-1 cells. However, the formation of PtdOH may be ex-
plained in part by a stimulation of a PLC activity followed
by that of a DAG kinase [27].
This is the ¢rst report indicating that an oleate-dependent
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Fig. 2. E¡ect of atRA on the hydrolysis of PtdCho in LA-N-1 nu-
clei. The experimental details are described in Section 2. Results are
the meansRS.E.M. of three experiments and represent the percent-
age increase of radioactivity of each water-soluble choline com-
pound relative to total nuclear lipids. The amount of the total ra-
dioactivity in the nuclear fraction is 100 000 cpm. The open bars
represent the control incubations and the ¢lled ones the atRA incu-
bations. **P6 0.01; *P6 0.05.
 
 
 
  
 
Fig. 3. E¡ect of GTPQS/PIP2 and oleate on the speci¢c activity of
PLD in LA-N-1 nuclei of control or atRA-treated cells. The experi-
mental details are described in Section 2. Results are the means
RS.E.M. of three experiments and represent the speci¢c activity of
nuclear PLD expressed in nmol of PtdOH+PtdEtOH/mg protein/h.
The amount of the total radioactivity in the nuclear fraction is
150 000 cpm. The open bars represent the control incubations and
the ¢lled ones the atRA incubations. The amount of PtdOH pro-
duced in nuclei of control and atRA-treated cells represents about
30% of the total production of PtdOH+PtdEtOH. ***P6 0.001.
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PLD is speci¢cally activated in nuclei of human-di¡erentiated
neuroblastoma cells. We hypothesize that distinct nuclear
PLDs may produce di¡erent molecular species of PtdOH
and consequently DAG by a phosphatidate phosphohydrolase
activity during cellular proliferation or di¡erentiation [8]. This
is in accordance with the recent observation of two distinct
sources of DAG in nuclei of proliferative and DMSO-dif-
ferentiated HL60 cells [28]. The production of di¡erent mo-
lecular species of PtdOH or DAG may activate di¡erent
isoforms of protein kinase C [29] leading to cellular pro-
liferation or di¡erentiation. Further investigations are re-
quired to con¢rm this hypothesis.
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